Papers

2 results

All Human Health Effects 25,424 Gut & Microbiome 6,526 Reproductive & Development 3,270 Food & Water 8,916 Nanoplastics 9,972 Detection Methods 17,548 Remediation 21,169 Marine & Wildlife 30,770 Environmental Sources 38,037 Policy & Risk 19,660

Article Tier 2

Empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children : a retrospective medical record review

Researchers retrospectively analyzed clinical outcomes for 53 pediatric patients with ESBL-producing E. coli and K. pneumoniae bacteremia treated with carbapenem or non-carbapenem empirical antibiotics between 2014 and 2019. They found a 30-day all-cause mortality rate of 17%, with 84.6% of non-carbapenem-treated patients switched to carbapenem therapy by day 2, suggesting non-carbapenem empirical therapy was frequently inadequate for this population.

2022 Research Square (Research Square)

Article Tier 2

Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review

Researchers reviewed medical records of children with bloodstream infections from antibiotic-resistant bacteria and found that starting with non-carbapenem antibiotics — a broader, less powerful class — did not increase mortality risk as long as treatment was quickly adjusted once lab results confirmed the specific bacteria involved.

2022 BMC Infectious Diseases 5 citations